• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

熊去氧胆酸治疗诱导的 GLOBE 评分变化与原发性胆汁性胆管炎患者肝移植无失败生存率相关。

Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

机构信息

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.

出版信息

Am J Gastroenterol. 2023 Jul 1;118(7):1196-1203. doi: 10.14309/ajg.0000000000002128. Epub 2022 Dec 14.

DOI:10.14309/ajg.0000000000002128
PMID:36621963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10298170/
Abstract

INTRODUCTION

Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score. We aimed to assess the association between changes in the GLOBE score (ΔGLOBE) and liver transplantation (LT)-free survival in patients with PBC who were treated with ursodeoxycholic acid (UDCA).

METHODS

Among UDCA-treated patients within the Global PBC cohort, the association between ΔGLOBE (ΔGLOBE 0-1 : during the first year of UDCA, ΔGLOBE 1-2 : during the second year) and the risk of LT or death was assessed through Cox regression analyses.

RESULTS

Overall, 3,775 UDCA-treated patients were included; 3,424 (90.7%) were female, the median age was 54.0 (interquartile range [IQR] 45.9-62.4) years, and the median baseline GLOBE score was 0.25 (IQR -0.47 to 0.96). During a median follow-up of 7.2 (IQR 3.7-11.5) years, 730 patients reached the combined end point of LT or death. The median ΔGLOBE 0-1 was -0.27 (IQR -0.56 to 0.02). Cox regression analyses, adjusted for pretreatment GLOBE score and ΔGLOBE 0-12 , showed that ΔGLOBE was associated with LT or death (adjusted hazard ratio 2.28, 95% confidence interval 1.81-2.87, P < 0.001). The interaction between baseline GLOBE score and ΔGLOBE 0-1 was not statistically significant ( P = 0.296). The ΔGLOBE 1-2 was associated with LT or death (adjusted hazard ratio 2.19, 95% confidence interval 1.67-2.86, P < 0.001), independently from the baseline GLOBE score and the change in GLOBE score during the first year of UDCA.

DISCUSSION

UDCA-induced changes in the GLOBE score were significantly associated with LT-free survival in patients with PBC. While the relative risk reduction of LT or death was stable, the absolute risk reduction was heavily dependent on the baseline prognosis of the patient.

摘要

简介

原发性胆汁性胆管炎(PBC)的治疗可以改善 GLOBE 评分。我们旨在评估 PBC 患者在接受熊去氧胆酸(UDCA)治疗后,GLOBE 评分(ΔGLOBE)的变化与肝移植(LT)无生存的相关性。

方法

在全球 PBC 队列中接受 UDCA 治疗的患者中,通过 Cox 回归分析评估 ΔGLOBE(ΔGLOBE 0-1:在 UDCA 的第一年期间,ΔGLOBE 1-2:在第二年期间)与 LT 或死亡风险之间的关系。

结果

总体而言,纳入了 3775 名接受 UDCA 治疗的患者;3424 名(90.7%)为女性,中位年龄为 54.0(四分位距[IQR] 45.9-62.4)岁,基线 GLOBE 评分为 0.25(IQR -0.47 至 0.96)。在中位随访 7.2(IQR 3.7-11.5)年后,730 名患者达到 LT 或死亡的联合终点。ΔGLOBE 0-1 的中位数为-0.27(IQR -0.56 至 0.02)。经预处理 GLOBE 评分和ΔGLOBE 0-12 调整的 Cox 回归分析表明,ΔGLOBE 与 LT 或死亡相关(调整后的危险比 2.28,95%置信区间 1.81-2.87,P <0.001)。基线 GLOBE 评分和ΔGLOBE 0-1 之间的交互作用无统计学意义(P = 0.296)。ΔGLOBE 1-2 与 LT 或死亡相关(调整后的危险比 2.19,95%置信区间 1.67-2.86,P <0.001),与基线 GLOBE 评分和 UDCA 治疗第一年 GLOBE 评分的变化无关。

讨论

UDCA 诱导的 GLOBE 评分变化与 PBC 患者的 LT 无生存显著相关。虽然 LT 或死亡的相对风险降低是稳定的,但绝对风险降低在很大程度上取决于患者的基线预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cd/10298170/9f363137b4ea/acg-118-1196-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cd/10298170/3a34df92158f/acg-118-1196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cd/10298170/9f363137b4ea/acg-118-1196-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cd/10298170/3a34df92158f/acg-118-1196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3cd/10298170/9f363137b4ea/acg-118-1196-g004.jpg

相似文献

1
Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.熊去氧胆酸治疗诱导的 GLOBE 评分变化与原发性胆汁性胆管炎患者肝移植无失败生存率相关。
Am J Gastroenterol. 2023 Jul 1;118(7):1196-1203. doi: 10.14309/ajg.0000000000002128. Epub 2022 Dec 14.
2
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.熊去氧胆酸治疗原发性胆汁性胆管炎患者肝移植无生存。
J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11.
3
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.熊去氧胆酸治疗原发性胆汁性胆管炎以预防肝移植或死亡的所需人数。
Gut. 2020 Aug;69(8):1502-1509. doi: 10.1136/gutjnl-2019-319057. Epub 2019 Dec 16.
4
Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.原发性胆汁性胆管炎患者应用熊去氧胆酸治疗后,根据碱性磷酸酶和 GLOBE 评分的肝移植无生存情况。
Aliment Pharmacol Ther. 2022 Nov;56(9):1408-1418. doi: 10.1111/apt.17226. Epub 2022 Sep 22.
5
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.熊去氧胆酸治疗原发性胆汁性胆管炎患者的风险评分系统的验证。
Am J Gastroenterol. 2019 Jul;114(7):1101-1108. doi: 10.14309/ajg.0000000000000290.
6
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.熊去氧胆酸治疗患者的预后评分可预测肝移植后复发原发性胆汁性胆管炎患者的移植物丢失和死亡率。
J Hepatol. 2024 Oct;81(4):679-689. doi: 10.1016/j.jhep.2024.05.010. Epub 2024 May 29.
7
A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.原发性胆汁性胆管炎中预后评分(梅奥、英国-原发性胆汁性胆管炎和 GLOBE)的比较。
Am J Gastroenterol. 2021 Jul 1;116(7):1514-1522. doi: 10.14309/ajg.0000000000001285.
8
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.原发性胆汁性胆管炎肝移植术后预防性熊去氧胆酸治疗的长期影响。
J Hepatol. 2020 Sep;73(3):559-565. doi: 10.1016/j.jhep.2020.03.043. Epub 2020 Apr 7.
9
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.熊去氧胆酸治疗肝移植后复发性原发性胆汁性肝硬化的长期生存情况及影响
Liver Transpl. 2007 Sep;13(9):1236-45. doi: 10.1002/lt.21124.
10
Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.熊去氧胆酸应答与代偿性肝硬化原发性胆汁性胆管炎患者死亡率降低相关。
Am J Gastroenterol. 2021 Sep 1;116(9):1913-1923. doi: 10.14309/ajg.0000000000001280.

引用本文的文献

1
Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis.原发性胆汁性胆管炎患者的二线治疗:一项网状Meta分析的系统评价
Liver Int. 2025 Jan;45(1):e16222. doi: 10.1111/liv.16222.
2
Ursodeoxycholic acid for the treatment of hepatic sarcoid: A pre-post pilot study.熊去氧胆酸治疗肝脏结节病:一项前后对照的试点研究。
Clin Exp Hepatol. 2024 Sep;10(3):194-196. doi: 10.5114/ceh.2024.141732. Epub 2024 Jul 25.
3
The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients.
在一大群美国原发性胆汁性胆管炎患者中,对用于预测熊去氧胆酸治疗反应的GLOBE和英国原发性胆汁性胆管炎风险评分进行外部验证。
J Clin Med. 2024 Aug 1;13(15):4497. doi: 10.3390/jcm13154497.
4
Prognostic scores in primary biliary cholangitis.原发性胆汁性胆管炎的预后评分
Future Sci OA. 2024 May 14;10(1):FSO975. doi: 10.2144/fsoa-2023-0203. eCollection 2024.
5
Causal associations between gut microbiota and Cholestatic liver diseases: a Mendelian randomization study.肠道微生物群与胆汁淤积性肝病之间的因果关联:一项孟德尔随机化研究。
Front Med (Lausanne). 2024 Jan 24;11:1342119. doi: 10.3389/fmed.2024.1342119. eCollection 2024.
6
Compensated liver cirrhosis: Natural course and disease-modifying strategies.代偿期肝硬化:自然病程及疾病修饰策略
World J Methodol. 2023 Sep 20;13(4):179-193. doi: 10.5662/wjm.v13.i4.179.